ライフサイエンスコーパス: EUS

1 EUS and MRI detect pancreatic lesions better than CT.

2 EUS appears useful to stage objectively and evaluate the

3 EUS can also guide needle aspiration of these lesions to

4 EUS detected malignant mediastinal lymphadenopathy more

5 EUS evaluation should be performed within 3-6 months for

6 EUS facilitates endoscopic drainage of pancreatic fluid

7 EUS FNA is more accurate for nodal staging and impacts o

8 EUS FNA resulting in a higher/worse stage than CT (41 pa

9 EUS FNA should be included in the preoperative staging a

10 EUS FNA was more sensitive (83% vs. 29%; P < 0.001) than

11 EUS had a sensitivity of 100% and specificity of 80% for

12 EUS has a central role in the initial anatomic staging o

13 EUS has an increasing role in treatment with fiducial pl

14 EUS has been invariably more accurate than computed tomo

15 EUS has evolved and is now dominated by the application

16 EUS is an accurate diagnostic tool for the detection of

17 EUS is an indispensable tool in making a preoperative di

18 EUS is inaccurate for staging after radiation and chemot

19 EUS is inaccurate for staging after radiation therapy an

20 EUS is limited for staging distant metastases (M), and t

21 EUS is superior to OGD for detecting GOV in children wit

22 EUS played a significant role in identifying patients wi

23 EUS plus EBUS also had higher sensitivity and higher neg

24 EUS post ablation may prevent the progression of EI and

25 EUS precluded surgery in 9 patients (12%) and influenced

26 EUS reflex electromyographic activity (EMG), innervation

27 EUS regions were marked on the maps.

28 EUS results have shown accuracy in the range of 75% for

29 EUS showed prominent mucosa, but no significant findings

30 EUS T plus N and postsurgery T plus N correlation showed

31 EUS was able to detect small metastases (less than 1 cm)

32 EUS was able to identify regional lymph nodes (RLN) in a

33 EUS was able to identify regional lymph nodes (RLNs) in

34 EUS was defined as a threshold >10 mA.

35 EUS was identified in the infarct in all 14 patients (11

36 EUS was performed when feasible.

37 EUS, MRI, and EUA are accurate tests for determining fis

38 EUS-FNA accurately and safely evaluates solid peri-intes

39 EUS-FNA as a first test (after CT) has high diagnostic y

40 EUS-FNA established tissue diagnosis in 70% of cases.

41 EUS-FNA has good accuracy in PCLs < 3 cm.

42 EUS-FNA identified MRLN in 27 of 31 (87.1%) patients ult

43 EUS-FNA identified MRLN in27/31 (87.1%) patients ultimat

44 EUS-FNA is able to detect occult metastasis to the CLNs

45 EUS-FNA is effective for identifying MRLN in patients wi

46 EUS-FNA sampling was diagnostic in 72 of 92 cases (78.3%

47 EUS-FNA was also useful to diagnose benign cysts, possib

48 EUS-FNA was performed in 457 patients with 554 lesions.

49 EUS-FNA was significantly better than CT at detecting di

50 EUS-FNA with histology of the specimens is a sensitive a

51 EUS-FNA, CT, and positron emission tomography detected m

52 EUS-guided fine-needle aspiration was performed on sites

53 EUS-RTFNA allows for local staging and tissue diagnosis

54 ave a more indolent clinical course; and (3) EUS-FNA may be useful for the diagnosis and management o

55 accuracy of all 3 modalities was > or =85%: EUS 29 of 32 (91%, confidence interval [CI] 75%-98%), MR

56 All gastric lymphomas had an abnormal EUS: eight with discrete tumor masses and eight with gas

57 f the pancreas to the digestive tract allows EUS to obtain detailed images of this organ.

58 nalyses, sensitivity of PET-%DeltaSUVmax and EUS for nodal disease was higher in squamous cell carcin

59 ses had very low-amplitude electrograms, and EUS could not be identified from electrogram amplitude a

60 In summary, ERCP and EUS are important tools for the management of benign and

61 he literature over the last year in ERCP and EUS as they apply to specific pancreatic disorders.

62 performance characteristics of CT, EUS, and EUS FNA for preoperative nodal staging of esophageal car

63 , and tumor stage determined by CT, EUS, and EUS FNA were associated with treatment decisions (P < 0.

64 re prospectively evaluated with CT, EUS, and EUS FNA.

65 , but most of the emphasis is on EUS-FNA and EUS-guided interventions.

66 TBNA, EBUS-FNA, and EUS-FNA performed sequentially as a single combined proc

67 Enhanced staging with laparoscopy and EUS helped in proper selection of patients and better ch

68 CT, MRI, and EUS detected a pancreatic abnormality in 11%, 33.3%, and

69 In 9 of 16 patients the results of OGD and EUS were concordant, that is, both positive (2) or both

70 al transplant underwent simultaneous OGD and EUS.

71 Clinical response and EUS staging were correlated with surgical pathology.

72 on of submucosal tumors of the GI tract, and EUS criteria have been devised for the identification an

73 n pancreatic malignancy and ERCP, as well as EUS can identify and sample the solid and cystic lesions

74 e role of EUS-guided fine-needle aspiration (EUS FNA) in this setting is unclear.

75 y of EUS, EUS-guided fine needle aspiration (EUS-fine needle aspiration), emerging cytologic markers

76 , ultrasound-guided, fine-needle aspiration (EUS-FNA) biopsy and were resected.

77 ic ultrasound-guided fine-needle aspiration (EUS-FNA) for diagnosis of metastases to the pancreas.

78 ic ultrasound-guided fine needle aspiration (EUS-FNA) for the diagnosis of solid pancreatic cancer is

79 opic ultrasound with fine-needle aspiration (EUS-FNA) is recommended in pancreatic cystic lesions (PC

80 trasonography-guided fine needle aspiration (EUS-FNA) of pancreatic cysts, but there is conflicting e

81 opic ultrasound with fine needle aspiration (EUS-FNA) remain the preferred methods.

82 ic ultrasound-guided fine needle aspiration (EUS-FNA) was allowed as an alternative procedure.

83 ic ultrasound-guided fine needle aspiration (EUS-FNA) was evaluated as a single test for the diagnosi

84 ic ultrasound-guided fine-needle aspiration [EUS-FNA]) is capable of sampling lymph nodes for PCR ana

85 Pathologic staging can be achieved at EUS using fine-needle aspiration (FNA) to obtain cytolog

86 nsufficient accuracy of endoscopic biopsies, EUS, and 18F-FDG PET(-CT) as single modalities for detec

87 ysis on the accuracy of endoscopic biopsies, EUS, and 18F-FDG PET(-CT) for detecting residual disease

88 studies on accuracy of endoscopic biopsies, EUS, or PET(-CT) for detecting locoregional residual dis

89 graphy-guided fine-needle aspiration biopsy (EUS-FNA) permits cytological confirmation of EUS finding

90 in [R] positivity of polypectomy or biopsy), EUS, CT or MRI, and/or (68)Ga-DOTA-TATE PET/CT.

91 s can be detected and sampled effectively by EUS-fine needle aspiration (FNA).

92 If no stone was found by EUS, ERCP would not be performed and patients were follo

93 seven patients, GOV were only identified by EUS.

94 The mean tumor size measured by EUS was 26.1 mm (range: 20-42 mm).

95 hort, identification of at least one MRLN by EUS was associated with lower median survival (353 vs 10

96 hort, identification of at least one MRLN by EUS was associated with lower median survival (353 vs. 1

97 or EPI, diagnosis of chronic pancreatitis by EUS and endoscopic pancreatic function testing and treat

98 patients who were positive for CBD stones by EUS, nine had successful ERCP, one failed ERCP (later tr

99 8 patients without evidence of CBD stones by EUS, no false-negative case was noted during the three-m

100 confirmed in 32 (1.6%) cases, 30 of them by EUS-FNA, and 2 by surgery.

101 50% or more reduction of tumor thickness by EUS postchemotherapy continues to be the best measure fo

102 Of 113 subjects with lung cancer, EUS was performed as a first test (after CT scan) for di

103 For intrahepatic CCA, EUS detected a higher percentage of RLN compared to cros

104 Clinical, EUS and pancreatic cystic fluid (PCF) data were prospect

105 tively enrolled in a blinded study comparing EUS, MRI, and examination under anesthesia (EUA).

106 rbidities, and tumor stage determined by CT, EUS, and EUS FNA were associated with treatment decision

107 mpare the performance characteristics of CT, EUS, and EUS FNA for preoperative nodal staging of esoph

108 hester were prospectively evaluated with CT, EUS, and EUS FNA.

109 EUS-guided fine needle aspiration cytology (EUS-FNA), and the newest emerging application is EUS-gui

110 d electrogram amplitude that best determines EUS is unknown.

111 supraspinal connections on chronic detrusor-EUS coordination.

112 show that the extent of recovery of detrusor-EUS coordination depends on injury severity and the degr

113 jured rats, the chronic recovery of detrusor-EUS coordination was very incomplete and correlated to d

114 njury site and complete recovery of detrusor-EUS coordination.

115 sible on color Doppler or even power Doppler EUS.

116 Hemorrhagic complications during EUS-guided pseudocyst drainage can occur, because the ve

117 FNA samples from each of 250 patients during EUS.

118 urting arterial bleeding precipitated during EUS-guided pseudocyst drainage which stopped instantaneo

119 diagnostic efficacy of linear echoendoscopy (EUS) for CBD stones.

120 d that alcohol is not required for effective EUS-guided pancreatic cyst ablation, and when alcohol is

121 Ultrasound elastography (EUS) is a new method that shows structural changes in ti

122 Low MI contrast enhanced EUS technique is expected to improve the differential di

123 and specificity of low MI contrast enhanced EUS using TIC analysis were 93.75% (95% CI = 77.77-98.91

124 and specificity of low MI contrast enhanced EUS using TIC were sensitivity and specificity of low MI

125 low mechanical index (MI) contrast-enhanced EUS.

126 during procedural sedation for elective ERCP/EUS by reducing the frequency of hypoxemia, severe hypox

127 61.5 +/- 9.7 years; male, 69%) received EUS (EUS group) and 3616 (63.2 +/- 10.9 years; male, 61.1%) w

128 cent findings regarding the accuracy of EUS, EUS-guided fine needle aspiration (EUS-fine needle aspir

129 The combination of EUS-FNA and EBUS-FNA (EUS plus EBUS) had higher estimated sensitivity (93% [39

130 les devoted to the standard applications for EUS, but most of the emphasis is on EUS-FNA and EUS-guid

131 T) findings of a lung mass were enrolled for EUS and results were compared with those from CT and pos

132 An emerging indication for EUS is the diagnosis and staging of cholangiocarcinoma.

133 , 67% of patients who underwent alcohol-free EUS-guided cyst chemoablation had complete ablation of c

134 Groups included image- (gastroscopy, EUS, and anatomical and/or functional imaging) positive

135 Under EUS guidance, a 19-gauge EUS fine needle was advanced transhepatically into the p

136 For iCCA, EUS detected a higher percentage of RLN compared to cros

137 This new method of identifying EUS provides complimentary information to the electrogra

138 In EUS group, EI occurred in 63 patients (type 1 EI in 35 a

139 mulus train duration produced a reduction in EUS ENG activity before and after SCT.

140 ew highlights advances over the last year in EUS in the evaluation of pancreatic neuroendocrine tumor

141 From its inception, EUS has been primarily utilized for staging cancer, asse

142 en the pursuit of new technologies including EUS.

143 Minimally invasive EUS-FNA with RT-PCR is capable of detecting expression o

144 FNA), and the newest emerging application is EUS-guided interventions.

145 Linear EUS had sensitivity, specificity, positive and negative

146 Linear EUS is safe and efficacious for the diagnosis of occult

147 When a CBD stone was disclosed by linear EUS, ERCP with stone extraction was performed.

148 ll on narrow-band imaging, and with a 20-MHz EUS probe, it was designated eusT1bN0.

149 +/- 10.9 years; male, 61.1%) without EUS (No-EUS group).

150 In No-EUS group, esophagopericardial fistula (EPF; n = 3,0.08%

151 s significantly greater than the accuracy of EUS morphology (57 of 112, 51%) or cytology (64 of 109,

152 on recent findings regarding the accuracy of EUS, EUS-guided fine needle aspiration (EUS-fine needle

153 negative predictive values, and accuracy of EUS-FNA with histology analysis of the specimens for dia

154 creatitis may be enhanced by ANN analysis of EUS imaging.

155 d and is now dominated by the application of EUS-guided fine needle aspiration cytology (EUS-FNA), an

156 e studies on the therapeutic applications of EUS have been published.

157 ill focus on the therapeutic applications of EUS.

158 The combination of EUS-FNA and EBUS-FNA (EUS plus EBUS) had higher estimate

159 inal diagnosis was based on a combination of EUS-FNA, surgery and follow-up of minimum 6 months in ne

160 EUS-FNA) permits cytological confirmation of EUS findings.

161 A multicenter prospective evaluation of EUS-FNA for primary diagnosis, staging, and/or follow-up

162 s study is to evaluate the staging impact of EUS for CCA including analysis by subtype.

163 s study is to evaluate the staging impact of EUS for CCA, including analysis by subtype.

164 onic bursts and phasic firing independent of EUS activity.

165 lysis improved the diagnostic performance of EUS imaging-AUC = 0.80 versus AUC = 60.

166 hortened intervals and/or the performance of EUS in 6-12 months directed towards lesions determined t

167 The performance of EUS-FNA for diagnosis of pancreatic metastases was analy

168 Performance of EUS-FNA with PCF analysis for the detection of malignanc

169 The results of EUS imaging, cyst fluid cytology, and cyst fluid tumor m

170 , there is controversy regarding the role of EUS fine-needle aspiration, the findings of which may en

171 As for the role of EUS in pancreatic cancer, recent technical advances in c

172 The role of EUS in restaging following neoadjuvant therapy remains c

173 last year demonstrate the important role of EUS in the diagnosis, prognosis, and treatment of pancre

174 e needle aspiration samples, and the role of EUS screening for patients with multiple endocrine neopl

175 data and some uncertainty as to the role of EUS within the diagnostic algorithm for patients with su

176 The role of EUS-guided fine-needle aspiration (EUS FNA) in this sett

177 The sensitivity of EUS-FNA for pancreatic adenocarcinoma is excellent (more

178 Cytological study of EUS-guided fine needle aspiration from the mass was sugg

179 e the diagnostic yield and optimal timing of EUS in patients with an intermediate or high likelihood

180 uracy of cPanNENs is increased by the use of EUS and somatostatin-receptor imaging and is higher in s

181 highlights recent advances in the utility of EUS in the clinical management of pancreatic neuroendocr

182 Limited data supports the utility of EUS-FNA for detection of MRLN in extrahepatic CCA, but t

183 As utilization of EUS is increasing, so is the evolution of the discipline

184 ompare prospectively the diagnostic yield of EUS-FNA samples obtained with slow-pull (SP) and with st

185 The diagnostic yields of EUS-FNA and CT for detection of metastases to the CLNs w

186 ho have a few nondiagnostic abnormalities on EUS, these results have poor correlation with the result

187 chronic pancreatitis should not be based on EUS findings alone.

188 s, and fluorescence in-situ hybridization on EUS-FNA samples may increase the yield and prove to be b

189 ions for EUS, but most of the emphasis is on EUS-FNA and EUS-guided interventions.

190 accurate than CT (87% vs. 51%; P < 0.001) or EUS (87% vs. 74%; P = 0.012) for nodal staging.

191 tractions were 252% larger and evoked phasic EUS activation 2.6 times as often as responses below thr

192 Posttreatment EUS findings did not correlate well with surgical pathol

193 ions has particular evolutionary properties (EUS, CS, SPR and MI).

194 valuated endoscopic biopsies, 11 qualitative EUS, 14 qualitative PET, 8 quantitative PET using maximu

195 al disease, 11 studies evaluated qualitative EUS with a pooled sensitivity and specificity of 68% and

196 oscopic biopsies, 96% and 8% for qualitative EUS, 74% and 52% for qualitative PET, 69% and 72% for PE

197 nts (61.5 +/- 9.7 years; male, 69%) received EUS (EUS group) and 3616 (63.2 +/- 10.9 years; male, 61.

198 the different neural pathways that regulate EUS activity are important to consider when inducing ner

199 in patients with a pancreatic cyst requiring EUS-FNA at multiple centers in Spain.

200 tations at presentation, blood test results, EUS and ERCP findings, and clinical manifestations durin

201 f 44 cases with resectable tumor on CT scan, EUS-FNA avoided thoracotomy in 14% of cases.

202 t delineating electrically unexcitable scar (EUS) within low-voltage infarct regions will locate reen

203 RF ablation lines connecting selected EUS regions abolished all inducible VTs in 10 patients (

204 adder and evoke external urethral sphincter (EUS) contraction (guarding reflex) to maintain continenc

205 ontractions and external urethral sphincter (EUS) electromyographic (EMG) activation during urodynami

206 External urethral sphincter (EUS) electromyography (EMG) was typical for the rat, wit

207 er pressure and external urethral sphincter (EUS) electroneurogram (ENG) evoked by PN stimulation bef

208 mic bursting of external urethral sphincter (EUS) EMG and expulsion of urine from the urethral meatus

209 External urethral sphincter (EUS) injections resulted in labelling of pudendal motone

210 The external urethral sphincter (EUS) plays a crucial role in maintaining urinary contine

211 d muscle of the external urethral sphincter (EUS) that is controlled by spinal and supraspinal circui

212 For initial anatomic staging, EUS results have consistently shown more than 80% accura

213 growth in the United States has been steady, EUS is exploding in areas of Asia and Eastern Europe.

214 , while FDG-PET/CT may be more accurate than EUS-FNA and CT scan for predicting nodal status and comp

215 ng that FDG-PET/CT may be more accurate than EUS-FNA and CT scan for predicting nodal status and comp

216 NA has higher sensitivity than TBNA and that EUS plus EBUS may allow near-complete minimally invasive

217 We hypothesized that EUS would detect early GOV and decrease the need for liv

218 nfirmation in other studies but suggest that EUS plus EBUS may be an alternative approach for mediast

219 The EUS responds to cutaneous as well as genital and rectal

220 However, the EUS EMG response is significantly larger when induced by

221 cy (+467%, n = 16) and tonic activity in the EUS (+56%, n = 7) whilst bursting activity in the EUS be

222 +56%, n = 7) whilst bursting activity in the EUS became desynchronised.

223 al nervous system neurons that innervate the EUS and the bladder in the female.

224 the lumbosacral plexus, which innervates the EUS.

225 omatic or visceral sources that modulate the EUS is lacking.

226 activation, anatomical reinnervation of the EUS demonstrated by retrograde neuronal labeling, normal

227 The activity of the EUS is modulated by bladder and urethra sensory neurons.

228 udy were to characterize the response of the EUS to perineal skin, genital, rectal, and urethral mech

229 the degree of coordinated activation of the EUS varied with the severity of initial injury and the d

230 ibition of the bladder and activation of the EUS, but mid-frequency (33 Hz) stimulation produced a mi

231 ion of the bladder without activation of the EUS.

232 bladder (micturition reflex) and relaxes the EUS (augmenting reflex).

233 The indications and role of therapeutic EUS have expanded rapidly in recent years.

234 rther expand the applications of therapeutic EUS.

235 lly, we will introduce potential therapeutic EUS interventions in the treatment of pancreatic neuroen

236 taging distant metastases (M), and therefore EUS is usually performed after a body imaging modality s

237 o provides a glimpse into the future through EUS-guided interventions.

238 ircuit isthmuses identified were adjacent to EUS.

239 ex voiding frequency (-60%, n = 7) and tonic EUS EMG activity (-38%, n = 6) or completely inhibited v

240 ow this threshold urethral flow evoked tonic EUS activity, indicative of the guarding reflex, that wa

241 Staging included endoscopic ultrasonography (EUS) and laparoscopy.

242 laparoscopy and endoscopic ultrasonography (EUS) and to improve R0 resection rates and tolerance by

243 tudies show that endoscopic ultrasonography (EUS) correlates well with endoscopic retrograde cholangi

244 ients undergoing endoscopic ultrasonography (EUS) fine-needle aspiration (FNA).

245 RPOSE OF REVIEW: Endoscopic ultrasonography (EUS) has taken on more of a therapeutic role in recent y

246 Analysis of endoscopic ultrasonography (EUS) images with an artificial neural network (ANN) prog

247 Endoscopic ultrasonography (EUS) may offer a diagnostic tool through the combination

248 Endoscopic ultrasonography (EUS) may replace endoscopic retrograde cholangiopancreat

249 ance imaging and endoscopic ultrasonography (EUS) should be used in combination as the preferred scre

250 the accuracy of endoscopic ultrasonography (EUS) to diagnose chronic pancreatitis.

251 ected to undergo endoscopic ultrasonography (EUS) to estimate EI post ablation.

252 raphy (ERCP) and endoscopic ultrasonography (EUS) under procedural sedation with a combination of opi

253 ach, as shown by endoscopic ultrasonography (EUS).

254 aging (MRI), and endoscopic ultrasonography (EUS).

255 laparoscopy and endoscopic ultrasonography (EUS).

256 t esophagoduodenoscopy with ultrasonography (EUS) that showed a 3- x 2-cm flat nodular mass with an 8

257 determine accuracy of endoscopic ultrasound (EUS) and magnetic resonance imaging (MRI) for evaluation

258 rd pancreaticobiliary endoscopic ultrasound (EUS) and other imaging modalities in the clinical manage

259 increasingly used in endoscopic ultrasound (EUS) for characterization of microvascularization, diffe

260 Endoscopic ultrasound (EUS) has a vital diagnostic role in pancreatic disorders

261 Endoscopic ultrasound (EUS) has emerged as the diagnostic measure of choice in

262 Endoscopic ultrasound (EUS) has gained increasing attention as a useful imaging

263 he clinical impact of endoscopic ultrasound (EUS) in staging NSCLC in absence of mediastinal lymphade

264 eatography (ERCP) and endoscopic ultrasound (EUS) in the management of patients with pancreatic-bilia

265 Endoscopic ultrasound (EUS) is a sensitive method for detection of GOV.

266 Endoscopic ultrasound (EUS) is a valuable tool in the diagnosis and management

267 Endoscopic ultrasound (EUS) is an important new tool in the staging of pancreat

268 Endoscopic ultrasound (EUS) is one of the fastest growing areas within gastroin

269 Endoscopic ultrasound (EUS) revealed a heteroechoic solid mass originating from

270 rtal venous blood via endoscopic ultrasound (EUS) to count portal venous circulating tumor cells (CTC

271 e include the role of endoscopic ultrasound (EUS), surgery in ZES patients with MEN1, pancreaticoduod

272 xamine the utility of endoscopic ultrasound (EUS), which is increasingly used in this setting to over

273 BACKGROUND & AIMS: Endoscopic ultrasound (EUS)-guided chemoablation with ethanol lavage followed b

274 upport the utility of endoscopic ultrasound (EUS)/fine needle aspiration (FNA) for detection of MRLNs

275 en patients underwent endoscopic ultrasound [EUS, odds ratio (OR) 2.69, 95% confidence interval (CI)

276 Under EUS guidance, a 19-gauge EUS fine needle was advanced tr

277 ients did not undergo MRI; 1 did not undergo EUS or EUA; and consensus could not be reached for 1.

278 study of PCLs < 3 cm (2007-2016) undergoing EUS-FNA.

279 In a randomized trial of patients undergoing EUS-FNA for pancreatic cyst evaluation, we found the ris

280 portal venous blood from patients undergoing EUS.

281 CLC and negative control subjects undergoing EUS for benign disease.

282 of previous extrapancreatic cancer underwent EUS-FNA from January/1997 to December/2010.

283 patients from the EBUS-TBNA group underwent EUS-FNA.

284 e hundred forty-one (341) patients underwent EUS and FNA of a pancreatic cystic lesion; 112 of these

285 37 patients underwent EUS-FNA for probable pancreas metastases.

286 mly assigned to 1 of 2 groups that underwent EUS-guided pancreatic cyst lavage with either 80% ethano

287 tion of CBD stones in patients who underwent EUS > 7 days after the initial clinical presentation (od

288 suspected choledocholithiasis who underwent EUS between June 2009 and January 2012 were retrospectiv

289 consecutive patients with CCA who underwent EUS staging at a single tertiary care center from 10/201

290 consecutive patients with CCA who underwent EUS staging at a single tertiary care center from Octobe

291 ients with diverse pathologies who underwent EUS with FNA, despite limited tissue sampling for FISH a

292 115 patients with PCLs < 3 cm who underwent EUS-FNA.

293 patients underwent surveillance imaging via EUS or MRCP and seventy-four patients met inclusion crit

294 When EUS-FNA was compared with EUS size criteria in lymph nod

295 bladder voiding contractions coincident with EUS EMG activation, anatomical reinnervation of the EUS

296 When EUS-FNA was compared with EUS size criteria in lymph node evaluation, specificity

297 locoregional staging is best performed with EUS-FNA, with CT scan of the thorax and abdomen and FDG-

298 Mediastinal lymph nodes were sampled with EUS-FNA in patients with NSCLC and negative control subj

299 firing during micturition in synchrony with EUS activity but, in addition, showed both tonic bursts

300 6 (63.2 +/- 10.9 years; male, 61.1%) without EUS (No-EUS group).